Literature DB >> 27364757

Toll-like receptors in the pathogenesis of pulmonary fibrosis.

Theodoros Karampitsakos1, Tony Woolard2, Demosthenes Bouros1, Argyris Tzouvelekis3.   

Abstract

Pulmonary fibrosis (PF) constitutes the end stage of a broad range of heterogeneous interstitial lung diseases, characterized by the destruction of the pulmonary parenchyma, deposition of extracellular matrix and dramatic changes in the phenotype of both fibroblasts and alveolar epithelial cells. More than 200 causes of pulmonary fibrosis have been identified so far, yet the most common form is idiopathic pulmonary fibrosis (IPF). IPF is a lethal lung disorder of unknown etiology with a gradually increasing worldwide incidence and a median survival of 3-5 years from the time of diagnosis. Despite intense research efforts, the pathogenesis remains elusive and no effective treatment is available. Accumulating body of evidence suggests an abnormal wound healing response followed by extracellular matrix deposition, destruction of lung architecture, ultimately leading to respiratory failure. The contribution of immune system in lung fibrogenesis had been largely underscored due to the absence of response to immunosuppressive agents; however, the premise that lung fibrosis has an immunologic background has been recently revived. Toll-like receptors (TLRs) are pattern recognition receptors (PRRs), which link innate and adaptive immune response and regulate wound healing. TLRs promote tissue repair or fibrosis in many disease settings including lung fibrosis, albeit with profound differences depending on the cellular microenvironment. This review summarizes the current state of knowledge regarding the mechanistic implications between TLRs and lung fibrosis and highlights the therapeutic potential of targeting TLR signaling at the ligand or receptor level.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Idiopathic Pulmonary Fibrosis; Immune response; Lung fibrosis; Toll like receptors; Wound healing

Mesh:

Substances:

Year:  2016        PMID: 27364757     DOI: 10.1016/j.ejphar.2016.06.045

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

1.  Topographic distribution of idiopathic pulmonary fibrosis: a hybrid physics- and agent-based model.

Authors:  Tyler J Wellman; Jarred R Mondoñedo; Gerald S Davis; Jason H T Bates; Béla Suki
Journal:  Physiol Meas       Date:  2018-06-28       Impact factor: 2.833

2.  Regulation of TLR4 signaling through the TRAF6/sNASP axis by reversible phosphorylation mediated by CK2 and PP4.

Authors:  Feng-Ming Yang; Hui-Ming Chang; Edward T H Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

3.  The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease.

Authors:  Ted R Mikuls; Rohit Gaurav; Geoffrey M Thiele; Bryant R England; Madison G Wolfe; Brianna P Shaw; Kristina L Bailey; Todd A Wyatt; Amy J Nelson; Michael J Duryee; Carlos D Hunter; Dong Wang; Debra J Romberger; Dana P Ascherman; Jill A Poole
Journal:  Int Immunopharmacol       Date:  2021-08-27       Impact factor: 4.932

4.  Ameliorative Effects of Arctigenin on Pulmonary Fibrosis Induced by Bleomycin via the Antioxidant Activity.

Authors:  Yueshang Wang; Xinpeng Li; Shiwen Pu; Xiao Wang; Lanping Guo; Lisheng Zhang; Zhen Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

5.  Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization.

Authors:  Feng Wang; Frank Stappenbeck; Liu-Ya Tang; Ying E Zhang; Simon T Hui; Aldons J Lusis; Farhad Parhami
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 6.  Metabolic Disorders in Chronic Lung Diseases.

Authors:  Ourania Papaioannou; Theodoros Karampitsakos; Ilianna Barbayianni; Serafeim Chrysikos; Nikos Xylourgidis; Vasilis Tzilas; Demosthenes Bouros; Vasilis Aidinis; Argyrios Tzouvelekis
Journal:  Front Med (Lausanne)       Date:  2018-01-18

Review 7.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 8.  Potential contribution of alveolar epithelial type I cells to pulmonary fibrosis.

Authors:  Michael Kasper; Kathrin Barth
Journal:  Biosci Rep       Date:  2017-11-21       Impact factor: 3.840

Review 9.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.